| Literature DB >> 27554801 |
Urmi Patel1, Sheeja Rajasingh1, Saheli Samanta1, Thuy Cao1, Buddhadeb Dawn1, Johnson Rajasingh2.
Abstract
Macrophages are a heterogeneous population of phagocytic cells present in all tissues. Recently, several drugs that target the epigenetic machinery have emerged as attractive molecules for treating infection and inflammation by modulating macrophages. Treatment of lipopolysaccharide (LPS)-challenged macrophages with epigenetic modifiers leads to phenotype switching. This could provide stimulatory/destructive (M1) or suppressive/protective (M2) therapeutic strategies, which are crucial in the cytokine milieu in which the macrophages reside. In this review, we provide an overview of macrophage functional diversity during various diseases, including infection, as well as the current status in the development and clinical utility of epigenetic modifiers.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27554801 PMCID: PMC5226865 DOI: 10.1016/j.drudis.2016.08.006
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851